REPRO-MED Systems (KRMD)
NASDAQ:KRMD
Want to see KRMD full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.02Last Year’s EPS
0.01Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive tone driven by strong top-line growth (22% YoY), substantial PST revenue acceleration (166% YoY), significant international expansion (35% YoY), near-breakeven adjusted EBITDA and minimal cash burn in Q1, alongside meaningful pipeline progress (two programs to Phase III, 510(k) submissions, EU MDR clearance). Key near-term risks include a 130-basis-point gross margin decline (partly tariff-related), an 11% increase in operating expenses, seasonal Q2 cash outflows, and lumpy international distributor-driven revenue timing. On balance, the operational and strategic momentum and reiterated guidance outweigh the noted headwinds.Company Guidance
Record Quarterly Revenue and Strong Top-Line Growth
Q1 2026 revenue of $11.8 million, up 22% year-over-year, described as a record start to the year and driven by recurring revenue from ~60,000 patients on the KORU platform.
Domestic and International Core Growth
Domestic core revenue grew 12% YoY, driven by new patient starts and competitive conversions; International core grew 35% YoY, led by prefilled syringe conversions and strong distributor orders in key EU markets.
Clinical Trial / PST Revenue Surge
PST (pharma/clinical trial) revenues increased 166% YoY driven by higher clinical trial product orders from advancing pharma collaborations.
Profitability and Cash Discipline Progress
Adjusted EBITDA was essentially breakeven at -$10,000 (a 95% improvement YoY); net losses improved 33% to $800,000; minimal cash usage of $0.1 million in Q1 and ending cash balance of $8.8 million.
Reiterated 2026 Guidance
Company reiterated full-year 2026 guidance: revenue $47.5M–$50M (growth 15%–22%), gross margin target 61%–63%, and expectations of positive adjusted EBITDA and positive cash flow for the full year.
Advancing Non-Ig Pipeline and Regulatory Progress
Two non-Ig pharma collaborations advanced to Phase III (including Empaveli for a 4th indication and an undisclosed partner restarting Phase III); submitted 510(k) for Freedom Infusion System with deferoxamine; eight active non-Ig opportunities representing >6 million annual infusions collectively.
Product and Market Expansion Milestones
EU MDR clearance for Freedom60 with prefilled syringe compatibility achieved; ongoing commercial rollout for RYSTIGGO (new label) and active Phesgo 510(k) engagement with FDA; development of next-gen Freedom60 pump with planned 510(k)/MDR filings in 2026.
Strategic Leadership Transition with Positive Tone
CEO transition planned (Adam Kalbermatten to become CEO on July 1st) described as well underway, with management expressing confidence in strategy execution and long-term targets ($100M revenue, >65% gross margin, 20%+ EBITDA margin).
KRMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KRMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $4.01 | $4.44 | +10.72% |
Mar 12, 2026 | $4.31 | $4.28 | -0.70% |
Nov 12, 2025 | $3.78 | $4.35 | +15.08% |
Aug 06, 2025 | $3.26 | $3.87 | +18.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does REPRO-MED Systems (KRMD) report earnings?
REPRO-MED Systems (KRMD) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is REPRO-MED Systems (KRMD) earnings time?
REPRO-MED Systems (KRMD) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KRMD EPS forecast?
KRMD EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.